<SEC-DOCUMENT>0000914475-22-000021.txt : 20220504
<SEC-HEADER>0000914475-22-000021.hdr.sgml : 20220504
<ACCEPTANCE-DATETIME>20220504073713
ACCESSION NUMBER:		0000914475-22-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220504
DATE AS OF CHANGE:		20220504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		22889842

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-20220504.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:058dfa52-45a3-48a2-b9ea-3502b7a02187,g:36c2fd74-8596-419e-9d22-788dadd310aa,d:89031dec0a2b441fa1b0ae752d8e01f0--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20220504</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF80L2ZyYWc6ZTg0MWVkOTY0NzgwNDkxZjhkNjdjMWVhOTUwMmJhNjcvdGFibGU6NzJjZGQ5NmE2ZWUwNGI2NDlmZjZmNzFjYzFjZDZkYzgvdGFibGVyYW5nZTo3MmNkZDk2YTZlZTA0YjY0OWZmNmY3MWNjMWNkNmRjOF8wLTEtMS0xLTU1NjM5_9a9987f0-1682-48ee-aa8a-cb1fc7eb0e20">false</ix:nonNumeric><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF80L2ZyYWc6ZTg0MWVkOTY0NzgwNDkxZjhkNjdjMWVhOTUwMmJhNjcvdGFibGU6NzJjZGQ5NmE2ZWUwNGI2NDlmZjZmNzFjYzFjZDZkYzgvdGFibGVyYW5nZTo3MmNkZDk2YTZlZTA0YjY0OWZmNmY3MWNjMWNkNmRjOF8xLTEtMS0xLTU1NjM5_31b73c03-7447-4968-9239-ced1d2b3b04f">0000914475</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20220504.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-04</xbrli:startDate><xbrli:endDate>2022-05-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i89031dec0a2b441fa1b0ae752d8e01f0_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTcx_7c1a4ff0-a535-46dc-a273-0b734c483ac2">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjM2NDk5_d0b30935-8c19-4f7e-99c6-575feeeef0e4">May&#160;4, 2022</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><img src="nbix-20220504_g1.jpg" alt="nbix-20220504_g1.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:420px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwNDkx_7c56d521-3547-4c88-af2e-6495972a2620">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:28.571%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMxNjk2_44244ff8-1489-4639-befd-c9dfaf8ceae8">Delaware</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/>(State or other jurisdiction<br/>of incorporation)</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.642%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:28.571%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMxNjk3_13497f14-2eaf-44ee-8905-6c4c45b2653f">0-22705</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/>(Commission<br/>File Number)</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.642%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:28.574%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMxNjk4_83061766-2f7c-4f9d-9750-3e492ebea09e">33-0525145</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/>(IRS Employer<br/>Identification No.)</span></div></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.428%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwMzg1_fb1cf23c-4667-48cd-8543-573038c868d8">12780 El Camino Real</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjM2NDkw_9c9571a0-979d-4cec-9051-bcac8c4046e5">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjM2NDkx_f90c515a-6e43-48f2-93c4-2b3c2c29e6bc">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div></div><div style="display:inline-block;max-width:7.142%;min-width:6.142%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.430%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwMzg5_06655084-5122-4c62-8361-88d3dca328de">92130</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Zip Code)</span></div></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwMzk2_4e67972e-2b2d-47a7-9a8a-a589f2048c65">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwNDAy_62249d40-cb9c-4840-94a5-74bc9bde76ae">617-7600</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTc1_3e2bb3a9-2616-4f8a-a2c1-db89790caf7c">&#9744;</ix:nonNumeric>  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTc2_a6e558f2-02fc-473f-ab9b-3dd57f922299">&#9744;</ix:nonNumeric>  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTc3_78db4081-0dfa-42fc-ad01-f5f62d7bffa1">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTc4_914d8226-d3e0-4dbf-8dc8-e1e4d46803a3">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGFibGU6YTcwNzgwMTIzNTExNGU3N2IwMDJkYTliNjJjZGIyY2MvdGFibGVyYW5nZTphNzA3ODAxMjM1MTE0ZTc3YjAwMmRhOWI2MmNkYjJjY18xLTAtMS0xLTYzODY1_f4e4cad6-2456-4cd4-8bd5-b0a3d9288962">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGFibGU6YTcwNzgwMTIzNTExNGU3N2IwMDJkYTliNjJjZGIyY2MvdGFibGVyYW5nZTphNzA3ODAxMjM1MTE0ZTc3YjAwMmRhOWI2MmNkYjJjY18xLTItMS0xLTYzODY3_4c6956a1-48f6-4573-a8b0-541b4b68a988">NBIX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGFibGU6YTcwNzgwMTIzNTExNGU3N2IwMDJkYTliNjJjZGIyY2MvdGFibGVyYW5nZTphNzA3ODAxMjM1MTE0ZTc3YjAwMmRhOWI2MmNkYjJjY18xLTQtMS0xLTYzODY5_a1208cb9-8bd5-4d86-be6f-2d21733b3c09">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTgw_7891c197-ca91-48ab-90fb-c373f7109ae3">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i89031dec0a2b441fa1b0ae752d8e01f0_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF83L2ZyYWc6ZjVmZDYwZTFjNTZjNGQ1NDk2OGU5NzdkOWQ3OTUwOTMvdGV4dHJlZ2lvbjpmNWZkNjBlMWM1NmM0ZDU0OTY4ZTk3N2Q5ZDc5NTA5M18xNjQ5MjY3NDQyNjM5_d0b30935-8c19-4f7e-99c6-575feeeef0e4">May&#160;4, 2022</ix:nonNumeric>, Neurocrine Biosciences, Inc. announced its financial results for the first quarter ended March&#160;31, 2022. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-2022331exhibit991.htm">Press Release dated May 4, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i89031dec0a2b441fa1b0ae752d8e01f0_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: <ix:nonNumeric contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xMC9mcmFnOjAzY2FlODIxYzcxYTQ1MzJhNzI0NmZmMDY4Yjc5M2E2L3RhYmxlOjZhYzAyODcwYTYzNDRiZGNhMDAxNmE0NzNjMzZkY2M1L3RhYmxlcmFuZ2U6NmFjMDI4NzBhNjM0NGJkY2EwMDE2YTQ3M2MzNmRjYzVfMi0wLTEtMS02Mzc4MS90ZXh0cmVnaW9uOjlkOWQ3NzlkZTMxMTQ1MGM4YTQ3NTgyMGEzMDY4MzBkXzE2NDkyNjc0NDE3MjM_d0b30935-8c19-4f7e-99c6-575feeeef0e4">May&#160;4, 2022</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Duly authorized officer and Principle Financial Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nbix-2022331exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1a085fc034e142efbf94a42e7d949729_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Neurocrine Biosciences Reports First Quarter 2022 Financial Results </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">and Reiterates 2022 Financial Guidance</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine) First Quarter Net Product Sales of $303 Million</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">INGREZZA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> (valbenazine) 2022 Net Product Sales Guidance Reiterated at $1.25 - $1.35 Billion</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SAN DIEGO, May 4, 2022 - Neurocrine Biosciences, Inc. (Nasdaq&#58; NBIX) today announced its financial results for the first quarter ended March&#160;31, 2022 and reiterated financial guidance for 2022.</font></div><div style="margin-bottom:12pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;INGREZZA&#8217;s first quarter performance reflects the opportunity we have to help patients living with tardive dyskinesia (TD). We completed our salesforce expansion in April and we now have three dedicated teams across psychiatry, neurology, and long-term care who are focused on improving diagnosis and treatment rates for TD,&#8221; said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. &#8220;With a growing product in INGREZZA, several mid-to-late-stage clinical data read-outs this year and next, and a strong financial profile, Neurocrine Biosciences continues to establish our position as a leading neuroscience-focused company.&#8221;</font></div><div style="margin-bottom:12pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Highlights</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:74.756%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(unaudited, in millions, except per share data)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Product sales, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">305.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">231.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">310.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">236.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP Research and Development (R&#38;D)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">102.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">89.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP Selling, General and Administrative (SG&#38;A)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">200.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">129.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">176.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">111.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP net income </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP earnings per share &#8211; diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP earnings per share &#8211; diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0.30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0.50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(unaudited, in millions)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr style="height:12pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,205.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,272.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INGREZZA Net Product Sales and Commercial Highlights&#58;</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">Net product sales were $303 million with total prescriptions (TRx) of approximately 57,600</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">Net product sales and TRx grew 32% and 33%, respectively, vs. first quarter of 2021</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">Improved levels of persistence and compliance for existing patients when compared to prior first quarters driven by strong commercial execution</font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">Record number of new patients </font></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">In April 2022, salesforce expansion was completed establishing separate psychiatry, neurology, and long-term care teams</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Highlights&#58;</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">First quarter 2022 GAAP net income and diluted earnings per share of $14 million and $0.14, respectively, compared with $32 million and $0.33, respectively, for first quarter 2021</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">First quarter 2022 non-GAAP net income and diluted earnings per share of $30 million and $0.30, respectively, compared with $49 million and $0.50, respectively, for first quarter 2021</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">Differences in first quarter 2022 GAAP and non-GAAP financial results compared with first quarter 2021 driven by&#58;</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.75pt">Increased R&#38;D expense in support of an expanded and advancing clinical portfolio</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.75pt">Increased SG&#38;A expense primarily due to ongoing commercial initiatives, including the TD Spotlight-branded direct-to-consumer INGREZZA advertising campaign which launched in May 2021 and deployment of the expanded salesforce in March 2022</font></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.8pt">At March&#160;31, 2022, the Company had cash, cash equivalents and marketable securities of $1.2&#160;billion</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A reconciliation of GAAP to non-GAAP financial results can be found in Table 3 and Table 4 at the end of this earnings release.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recent Events&#58;</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.15pt">In March 2022, Mitsubishi Tanabe Pharma Corporation (MTPC) received Japanese Ministry of Health, Labour and Welfare approval for DYSVAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (valbenazine) for the treatment of tardive dyskinesia in Japan. Under the terms of the license agreement, the Company is entitled to receive a milestone payment of $20 million upon MTPC's first commercial sale of DYSVAL in Japan, which is expected to occur in the second quarter of 2022.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.15pt">In April 2022, Neurocrine Biosciences presented Phase 3 data for the KINECT-HD study evaluating valbenazine for chorea associated with Huntington disease. In the study, valbenazine met the primary endpoint of significant (p&#60;0.0001) improvement in chorea severity versus placebo as measured by the Unified Huntington&#8217;s Disease Rating Scale (UHDRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Total Maximal Chorea (TMC) Score, with improvements beginning in week 2. Clinically meaningful results, demonstrated by greater response rates, were seen by clinicians (CGI-C) and patients (PGI-C) for valbenazine versus placebo. In addition, the safety profile was consistent with the known safety profile of valbenazine. The Company plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in the second half of 2022.  </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Reiterated 2022 INGREZZA Sales and Operating Expense Guidance&#58;  </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INGREZZA Net Product Sales </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,250&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,350&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP R&#38;D expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">380&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">415&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">325&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">360&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GAAP SG&#38;A expense </font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">720&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">735&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">605&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">620&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">INGREZZA sales guidance for fiscal 2022 reflects approximately 20% year-over-year growth, at the mid-point of the range, and is based on recent trends, an anticipated improving COVID-19 related environment throughout the year, and benefit from our recently completed salesforce expansion during the second half of 2022. If new COVID-19 related disruptions emerge, the Company&#8217;s ability to meet these expectations could be negatively impacted.</font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">GAAP R&#38;D guidance includes amounts for milestones that are probable of achievement or have been achieved and (ii) amounts for in-process research and development once significant collaboration and licensing arrangements have been completed. GAAP R&#38;D Guidance includes approximately $7 million of milestone expense for the Xenon collaboration which was achieved in January 2022. </font></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.5pt">Non-GAAP guidance adjusted to exclude estimated non-cash stock-based compensation expense of $60 million in R&#38;D and $110 million in SG&#38;A.</font></div><div style="margin-top:12pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Based upon Federal NOL&#8217;s and tax credits, the Company expects to begin making cash payments for Federal income tax beginning in the fourth quarter of 2022.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expected Future Milestones and Key Activities</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Program</font></td><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Indication</font></td><td colspan="3" style="background-color:#0070c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Expected Milestones &#47; Key Activities</font></td></tr><tr style="height:33pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Valbenazine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">*</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Selective VMAT2 Inhibitor)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chorea in Huntington Disease</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">File Supplemental New Drug Application in Second Half (2H) 2022</font></div></td></tr><tr style="height:42pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjunctive Treatment of Schizophrenia</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Data from 1st Registrational Study in 2023</font></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dyskinetic Cerebral Palsy</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Registrational Data in 2024</font></div></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-827104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">**</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Selective T-Type Ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:1.12pt;vertical-align:baseline">V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Channel Blocker)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Essential Tremor</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Phase 2 Data in Mid-2022</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Rare Pediatric Epilepsy&#58; CSWS</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Phase 2 Data in 2H 2022</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-1117568</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#8224;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Selective M4 Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Treatment of Schizophrenia</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiate Phase 2 Study in 2022</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Chemical Entity</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Neurological or Psychiatric Indication</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initiate Phase 1 Study in 2022</font></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Crinecerfont</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(CRF1 Receptor Antagonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Congenital Adrenal Hyperplasia (Adult)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-Line Registrational Data in 2023</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Congenital Adrenal Hyperplasia (Pediatric)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Top-Line Registrational Data in 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NBI-1065845</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#8225;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(AMPA Potentiator)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Inadequate Response to Treatment in </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Major Depressive Disorder</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phase 2 Data in 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-1065846</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#8225;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(GPR-139 Agonist)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anhedonia in Major Depressive Disorder</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phase 2 Data in 2023</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">NBI-921352</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#8734;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Selective Na</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.6 Channel Blocker)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Focal Onset Seizure in Adults</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phase 2 Data in 2023</font></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key&#58; VMAT2 &#61; Vesicular Monoamine Transporter 2&#59; Ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">V </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#61; Calcium Channel, Voltage-Gated&#59; CSWS &#61; Epileptic Encephalopathy with Continuous Spike and Wave During Sleep&#59; M4&#61; M4 Muscarinic Receptor&#59; CFR1 &#61; Corticotropin-Releasing Factor Type 1&#59; AMPA &#61; Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid&#59; GPR &#61; Orphan G Protein Coupled Receptor&#59; Na</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.6 &#61; Sodium Channel, Voltage-Gated</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurocrine Bioscience Partners&#58; * Mitsubishi Tanabe Pharma Corporation has commercialization rights in East Asia&#59; <br>** In-Licensed from Idorsia Pharmaceuticals&#59; &#8224; In-Licensed from Sosei Group Corporation&#59; &#8225; Partnered with Takeda Pharmaceutical Company Limited&#59; &#8734; In-Licensed from Xenon Pharmaceuticals</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast Today at 8&#58;00 AM Eastern Time</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neurocrine Biosciences will hold a live conference call and webcast today at 8&#58;00 a.m. Eastern Time (5&#58;00 a.m. Pacific Time). Participants can access the live conference call by dialing 800-895-3361 (US) or 785-424-1062 (International) using the conference ID&#58; NBIX. The webcast can also be accessed on Neurocrine Biosciences&#8217; website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">About Neurocrine Biosciences</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose&#58; to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company&#8217;s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie)</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to the financial results and financial guidance that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this press release also contains the following non-GAAP financial measures&#58; non-GAAP R&#38;D expense, non-GAAP SG&#38;A expense, and non-GAAP net income and net income per share. When preparing the non-GAAP financial results and guidance, the Company excludes certain GAAP items that management does not consider to be normal, including recurring cash operating expenses that might not meet the definition of unusual or non-recurring items. In particular, these non-GAAP financial measures exclude&#58; non-cash stock-based compensation expense, non-cash interest expense related to convertible debt, changes in fair value of equity security investments and certain adjustments to income tax expense. These non-GAAP financial measures are provided as a complement to results provided in accordance with GAAP as management believes these non-GAAP financial measures help indicate underlying trends in the Company's business, are important in comparing current results with prior period results and provide additional information regarding the Company's financial position. Management also uses these non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally and to manage the Company's business and evaluate its performance. The Company provides guidance regarding combined R&#38;D and SG&#38;A expenses on both a GAAP and a non-GAAP basis. A reconciliation of these GAAP financial results to non-GAAP financial results is included in the attached financial information.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to&#58; the benefits to be derived from our products and product candidates&#59; the value our products and&#47;or our product candidates may bring to patients&#59; the continued success of INGREZZA&#59; our financial and operating performance, including our future revenues, expenses, or profits&#59; our collaborative partnerships&#59; expected future clinical and regulatory milestones&#59; expectations regarding our ability to adapt our business to the evolving COVID-19 pandemic globally, mitigate its impact on our business, including our ability to continue conducting our ongoing clinical trials and other development activities, to protect the safety and well-being of our employees, to continue to support uninterrupted supply of INGREZZA, and to otherwise advance our business objectives&#59; and the timing of the initiation and&#47;or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are&#58; our future financial and operating performance&#59; risks associated with the commercialization of INGREZZA and ONGENTYS&#59; the impact of the evolving COVID-19 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">pandemic globally on our business and the business operations of our customers, collaborators, vendors, and clinical trial sites including the impact on the ability of patients to have in-person visits with their health care provider&#59; risks related to the development of our product candidates&#59; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties&#59; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates&#59; risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, COVID-19 or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials&#59; risks that the potential benefits of the agreements with our collaboration partners may never be realized&#59; risks that our products, and&#47;or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse&#59; risks associated with potential generic entrants for our products&#59; and other risks described in our periodic reports filed with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">###</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Contact&#58; Neurocrine Biosciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tony Jewell (Media)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">858-617-7578<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;neurocrine.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Todd Tushla (Investors)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">858-617-7143</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;neurocrine.com</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.6&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income and other, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for (benefit from) income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and debt securities available-for-sale</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,144.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,072.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,144.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,072.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.359%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net income</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense - R&#38;D</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense - SG&#38;A</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest related to convertible senior notes </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of equity security investments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect related to reconciling items </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net income </font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP </font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP </font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. Reflects unrealized gain recognized to adjust equity security investments to fair value.</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Estimated income tax effect of non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration any valuation allowance and adjustments to exclude tax benefits or expenses associated with non-cash stock-based compensation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note&#58; Beginning in the third quarter of 2021, milestone payments received from licenses and collaborations, milestones paid related to licenses and collaborations, non-cash collaboration revenue, and acquired in-process research and development are no longer excluded from non-GAAP financial results. First quarter 2021 non-GAAP financial results have been updated for comparability to current year periods.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE 4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP TO NON-GAAP EXPENSES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP R&#38;D</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP R&#38;D</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP SG&#38;A</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP SG&#38;A</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20220504.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:058dfa52-45a3-48a2-b9ea-3502b7a02187,g:36c2fd74-8596-419e-9d22-788dadd310aa-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20220504" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20220504">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220504_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220504_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurocrine.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nbix-20220504_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:058dfa52-45a3-48a2-b9ea-3502b7a02187,g:36c2fd74-8596-419e-9d22-788dadd310aa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_26c56574-c961-42ca-bd78-fa38bd3e5185_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bf926285-cf02-4136-a1c3-7e3ee9371cd6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_88d1fa86-91c8-4fcc-b85a-0a1fa5b53adf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8d9670c0-55f9-4392-a663-0fb4d1c70333_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_febc1b10-829b-44a3-b2b5-0762dec9603d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a1053d44-7d39-46ed-9351-d7aeedaad338_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a8bac3b8-528f-4c2c-bf54-ccfdad0854e8_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_4d306b84-15a2-4ed3-9038-a295872c6ac6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_904a213c-b0ed-4b8d-8ebe-7892f6491101_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9ba0ce62-3d28-4923-bfc9-93ff937cac80_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7010b031-7500-406f-ace9-1d4c015b4469_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_7e0c225f-e38e-46f5-babe-0d092c64fc7f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_56c2cccd-5c47-4ec2-a8e4-d8125c001264_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a9c5f977-c4a4-4209-8e92-e19eb9684283_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0f6ec701-4965-453e-9aaa-96af43ef1c9a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4b91eeef-6f40-4124-a151-44c4cf90b981_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_51bd1011-7deb-4b28-b0c2-72034feb279c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5d0a63b6-bd65-4021-bad8-6d1a7e333546_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8f66a14b-abe2-4c35-b8d1-adacd387fc9d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cd8a6d02-6021-4880-88df-7efe40ff4c38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b24ebb90-e84a-4b6c-9703-7b0d0ce3d54c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7447ff3f-d761-42ef-81c2-660e9a6dd19e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nbix-20220504_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:058dfa52-45a3-48a2-b9ea-3502b7a02187,g:36c2fd74-8596-419e-9d22-788dadd310aa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20220504.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5c174cbf-8e2c-4a8e-a1e9-cd102a62d0f9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_DocumentType_5c174cbf-8e2c-4a8e-a1e9-cd102a62d0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_501b440d-b40f-43c2-ae7f-86ef3a2dc6fa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_DocumentPeriodEndDate_501b440d-b40f-43c2-ae7f-86ef3a2dc6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bb5bdea6-80bf-401b-8758-43cc4f1ef70e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityRegistrantName_bb5bdea6-80bf-401b-8758-43cc4f1ef70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a17d0079-da8f-4ac5-a530-f0b0cabfe7c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a17d0079-da8f-4ac5-a530-f0b0cabfe7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c4133507-3aae-4c4f-9399-d7441e214384" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityFileNumber_c4133507-3aae-4c4f-9399-d7441e214384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9209861a-8527-44f1-9022-84375cac88a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityTaxIdentificationNumber_9209861a-8527-44f1-9022-84375cac88a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cbbe31a4-48e4-4493-9730-30a95981098b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityAddressAddressLine1_cbbe31a4-48e4-4493-9730-30a95981098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_131921c6-5a60-4d2b-bf3f-7c190a9629ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityAddressCityOrTown_131921c6-5a60-4d2b-bf3f-7c190a9629ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_eaf677ec-d9cf-466a-896d-349326f4bd65" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityAddressStateOrProvince_eaf677ec-d9cf-466a-896d-349326f4bd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0505c546-20b9-4849-bba4-77755ad84659" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityAddressPostalZipCode_0505c546-20b9-4849-bba4-77755ad84659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_451c1bf5-d73b-40a0-95ba-b208b37174a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_CityAreaCode_451c1bf5-d73b-40a0-95ba-b208b37174a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5536b010-9e18-4665-becf-77cbbafd1539" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_LocalPhoneNumber_5536b010-9e18-4665-becf-77cbbafd1539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_9b438b08-b588-4bef-93b2-1850d4fe1c1f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_WrittenCommunications_9b438b08-b588-4bef-93b2-1850d4fe1c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_1fcbea8b-911a-4f62-a13a-2f44ca6bf161" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_SolicitingMaterial_1fcbea8b-911a-4f62-a13a-2f44ca6bf161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e9d674f3-7eff-4845-8913-024cd8549425" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_PreCommencementTenderOffer_e9d674f3-7eff-4845-8913-024cd8549425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3769d1f2-55ba-4c60-aa69-0c844b678e9d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3769d1f2-55ba-4c60-aa69-0c844b678e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8e61289a-65b9-46a6-9082-5cfaa0448ac9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_Security12bTitle_8e61289a-65b9-46a6-9082-5cfaa0448ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b37bba71-6f7e-4c55-86d2-035c4a58c940" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_TradingSymbol_b37bba71-6f7e-4c55-86d2-035c4a58c940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e9f28917-d5d8-494d-81ea-373b51e888e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_SecurityExchangeName_e9f28917-d5d8-494d-81ea-373b51e888e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_967b7224-de94-46ce-b9d2-b2b164ffacb0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityEmergingGrowthCompany_967b7224-de94-46ce-b9d2-b2b164ffacb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9c7e34c8-2877-4e54-b70d-f94cacc607ac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_AmendmentFlag_9c7e34c8-2877-4e54-b70d-f94cacc607ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_28f88367-96c9-4e75-b350-1562bd334065" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8fb39b4c-5ffb-4bc9-9347-318091e33e11" xlink:to="loc_dei_EntityCentralIndexKey_28f88367-96c9-4e75-b350-1562bd334065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>nbix-20220504_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20220504_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MR:G++?KO,[ZZ=-["QGBEC:/'2X35&/LW**Y[OF]ZFI[;;NWH?=GBS]I;X>^
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M0+.< Y>UE3?-Z+\[GXK+PHXSIT7EN'QT?J[TM[2HE9[KEY7OU2=F?G)^Q?\
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MCO-6\(Z3<:??:A;?9)GDOIK@-'N#XP[$#D#D<UZ^,XCHXC!.C)/G:\K7^_\
M0_-N&_ W,\EXKI9G0JPEA:<W)7E+VG*TTDURVNKVOS:VOI>Q^;O_  4L_P"3
MVO&W^]:?^DD-7OV9O^"B_BK]ESX9_P#"+Z/H/A_4;/[7+>>=>&;S=TF,CY6
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MU+6MTNN37EI(XZ+-$YRRD\'!Z=CTKZ]M[>.TMXXHD6..-0B(HPJ@<  >@I]
M'S-^P!^UOXJ^*^K^*OAK\4-/33?BA\/91%?2PQ%+;6;<G"W4? 7NN0O!#HP
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M9SRTLC=7D8\LQZGVP*ZJBBOGI2<G=[GXQ6K5*U256JW*4G=MZMM[ML*^??\
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M*/C9_P $]O@_^T5X]F\3^,O!\.M:Y<0QV\ERU]<Q%DC!"#;'(J\ GM7*V_\
MP2*_9XM+F.:/X=6JR0NLB'^T[WAE((/^N]10!Q7_  49_P"3TOV3_P#L:[O^
M5M7UAX^\":3\4/!.J^'==LH=0T?6K62SO+:4966-P01['G((Y! (Y%8OQ%^
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MY('-4?CO^PK\)?VEM3&H>,_ ^CZKJB@+]O0-;79 Z9EB*NV.VXG%<_\ "O\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139684930478424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  04,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>nbix-20220504_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20220504.xsd" xlink:type="simple"/>
    <context id="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-04</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF80L2ZyYWc6ZTg0MWVkOTY0NzgwNDkxZjhkNjdjMWVhOTUwMmJhNjcvdGFibGU6NzJjZGQ5NmE2ZWUwNGI2NDlmZjZmNzFjYzFjZDZkYzgvdGFibGVyYW5nZTo3MmNkZDk2YTZlZTA0YjY0OWZmNmY3MWNjMWNkNmRjOF8wLTEtMS0xLTU1NjM5_9a9987f0-1682-48ee-aa8a-cb1fc7eb0e20">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF80L2ZyYWc6ZTg0MWVkOTY0NzgwNDkxZjhkNjdjMWVhOTUwMmJhNjcvdGFibGU6NzJjZGQ5NmE2ZWUwNGI2NDlmZjZmNzFjYzFjZDZkYzgvdGFibGVyYW5nZTo3MmNkZDk2YTZlZTA0YjY0OWZmNmY3MWNjMWNkNmRjOF8xLTEtMS0xLTU1NjM5_31b73c03-7447-4968-9239-ced1d2b3b04f">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTcx_7c1a4ff0-a535-46dc-a273-0b734c483ac2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjM2NDk5_d0b30935-8c19-4f7e-99c6-575feeeef0e4">2022-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwNDkx_7c56d521-3547-4c88-af2e-6495972a2620">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMxNjk2_44244ff8-1489-4639-befd-c9dfaf8ceae8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMxNjk3_13497f14-2eaf-44ee-8905-6c4c45b2653f">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMxNjk4_83061766-2f7c-4f9d-9750-3e492ebea09e">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwMzg1_fb1cf23c-4667-48cd-8543-573038c868d8">12780 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjM2NDkw_9c9571a0-979d-4cec-9051-bcac8c4046e5">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjM2NDkx_f90c515a-6e43-48f2-93c4-2b3c2c29e6bc">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwMzg5_06655084-5122-4c62-8361-88d3dca328de">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwMzk2_4e67972e-2b2d-47a7-9a8a-a589f2048c65">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xMDk5NTExNjMwNDAy_62249d40-cb9c-4840-94a5-74bc9bde76ae">617-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTc1_3e2bb3a9-2616-4f8a-a2c1-db89790caf7c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTc2_a6e558f2-02fc-473f-ab9b-3dd57f922299">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTc3_78db4081-0dfa-42fc-ad01-f5f62d7bffa1">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTc4_914d8226-d3e0-4dbf-8dc8-e1e4d46803a3">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGFibGU6YTcwNzgwMTIzNTExNGU3N2IwMDJkYTliNjJjZGIyY2MvdGFibGVyYW5nZTphNzA3ODAxMjM1MTE0ZTc3YjAwMmRhOWI2MmNkYjJjY18xLTAtMS0xLTYzODY1_f4e4cad6-2456-4cd4-8bd5-b0a3d9288962">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGFibGU6YTcwNzgwMTIzNTExNGU3N2IwMDJkYTliNjJjZGIyY2MvdGFibGVyYW5nZTphNzA3ODAxMjM1MTE0ZTc3YjAwMmRhOWI2MmNkYjJjY18xLTItMS0xLTYzODY3_4c6956a1-48f6-4573-a8b0-541b4b68a988">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGFibGU6YTcwNzgwMTIzNTExNGU3N2IwMDJkYTliNjJjZGIyY2MvdGFibGVyYW5nZTphNzA3ODAxMjM1MTE0ZTc3YjAwMmRhOWI2MmNkYjJjY18xLTQtMS0xLTYzODY5_a1208cb9-8bd5-4d86-be6f-2d21733b3c09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xL2ZyYWc6ZWRmYmM3NTk3NTBjNDQ3ZDgyZjk0MDc0NjMzZTIzYjkvdGV4dHJlZ2lvbjplZGZiYzc1OTc1MGM0NDdkODJmOTQwNzQ2MzNlMjNiOV8xNTgw_7891c197-ca91-48ab-90fb-c373f7109ae3">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF83L2ZyYWc6ZjVmZDYwZTFjNTZjNGQ1NDk2OGU5NzdkOWQ3OTUwOTMvdGV4dHJlZ2lvbjpmNWZkNjBlMWM1NmM0ZDU0OTY4ZTk3N2Q5ZDc5NTA5M18xNjQ5MjY3NDQyNjM5_d0b30935-8c19-4f7e-99c6-575feeeef0e4">2022-05-04</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5MDMxZGVjMGEyYjQ0MWZhMWIwYWU3NTJkOGUwMWYwL3NlYzo4OTAzMWRlYzBhMmI0NDFmYTFiMGFlNzUyZDhlMDFmMF8xMC9mcmFnOjAzY2FlODIxYzcxYTQ1MzJhNzI0NmZmMDY4Yjc5M2E2L3RhYmxlOjZhYzAyODcwYTYzNDRiZGNhMDAxNmE0NzNjMzZkY2M1L3RhYmxlcmFuZ2U6NmFjMDI4NzBhNjM0NGJkY2EwMDE2YTQ3M2MzNmRjYzVfMi0wLTEtMS02Mzc4MS90ZXh0cmVnaW9uOjlkOWQ3NzlkZTMxMTQ1MGM4YTQ3NTgyMGEzMDY4MzBkXzE2NDkyNjc0NDE3MjM_d0b30935-8c19-4f7e-99c6-575feeeef0e4">2022-05-04</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;%!+ 0(4 Q0    ( *4\I%3X_+\D[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *4\I%297)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ I3RD5-W_X5@U!   +1   !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *4\I%2?H!OPL0(  .(,
M   -              "  7D,  !X;"]S='EL97,N>&UL4$L! A0#%     @
MI3RD5)>*NQS     $P(   L              ( !50\  %]R96QS+RYR96QS
M4$L! A0#%     @ I3RD5*K$(A8S 0  (@(   \              ( !/A
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *4\I%0D'INBK0   /@!   :
M              "  9X1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( *4\I%1ED'F2&0$  ,\#   3              "  8,2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  ,T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-20220504.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nbix-20220504.htm">nbix-20220504.htm</File>
    <File>nbix-20220504.xsd</File>
    <File>nbix-20220504_lab.xml</File>
    <File>nbix-20220504_pre.xml</File>
    <File>nbix-2022331exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20220504_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20220504.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "nbix-20220504.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20220504_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20220504_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20220504.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20220504",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220504.htm",
      "contextRef": "i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.neurocrine.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220504.htm",
      "contextRef": "i591f088aafdb4fbcaa30bd5838228435_D20220504-20220504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000914475-22-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-22-000021-xbrl.zip
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M&T0RL,-<T26V9 NR5SD2X)\A0@WE#H]KM]4X81Y+&%BS=(?UX5:IGN8V&*0
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M.XW??$<H:D^B2K7BAZCS7Z\^^@]02P,$%     @ I3RD5(Q@TBEL @  = <
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M)C>YIS_/>9.0I\G+@&N/=?5U 5145(#_*#< >06@J@-Q=P4 # T!D@  @ Y
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M:Q9PE9J*$CQJ5@ (0"1\_3Q^JA;&95C?W%P?-?EG5#0G>,,WI2..WM55_3*
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M<9/GRN>"$YH2P_-F-LY%7R>,Y(Q'#"R.3Z>[*;%Y#PW4E,6=H;.PP6-B+F1
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M*$E]'L>UHMPC<]O2O1RJ5$P&=)AXL@,SN+4E!VCQBT_TCA$1ATH&PZQ@X[
M(0</WG2$GT+#H*%B@DVL9M$'4B!VD\"ZM-Q]F SC(?@V)_(X359KK32Y"JVG
MNM_,_D!-&L[F(IZ"63K2MLM^]#DUUJB(SU]/8;E!Y'[>FGOERVG.?!,>F4+
M=W/(&4?[%SD2,LL'*6T2I.,9#&R"_X+O$0M)0\!+U4#&[=<CW4HMOPR^&UT/
MSJI[^7E0*J\PLX]GZ\O]989]Z+,5)@44;60-$[OMK[KQ5^6F5VH;:[.#A$=^
MMM/ '3\?W2L#O4%RGBPEY=-"U5!#HI#-ZLFR@H_[]^3T$_3Y0N157(0JS1QT
MOWS7*IPV#@Q4?(VMK:RN,A"Z_"A%U^9#'@# IH^(+I',&VF 6IW/DWH'MY8G
MP4:9/+).?:FV_O5SQE**T/>@Y3@0W74GO'8O]PEI+)X,2)C2PP= 5:MQE-Y&
M,X11CI*^7<,X*,!H6%55FXDUD>G4S?*]?+4-X%M/_;:-HQ:T_'V):JXX>=^X
M?@QQCPSHL\C&AT$H>(*CQ(5F&1,44RU5$%:P,WFWCC-+T*Q[4]?G1J>7+S=U
MDCPMQ\Y824)&"-AFHTZ^9NP YI70CB[GSY4+IJW$)K-8Y<X,R!P=:8SZ&$P3
MAHGI4&VG%="LSPJII&1!Z]FW[8O]\NZAWP=L*D)6E[,_H &GE(GO&FD)?H6@
M7# <+-8ER[0@+6XW4-7(I:"?-!";*7RR#4Y&,JI3!6+ *-V(E5">\OU#J%88
MQSNVX7Q)Y92?C%XTRZ&7//56Q3H$G):5NYGL.FQ/_+X5%_P6"DH6E?C[IE^2
MC4I\0(L'@%6Y,37I=-3(/3!B(3QFX#*[>>Q#@XO,1;=:V4*DU=T>!^C_L?J5
M?SMEI"*.%)*A>0.2">2"X!TGR_=)O5ZE'LK*(UK)IQ+"93L?_=K^4T%,@B/R
M:%MQE%9,LULU<BH^RX<'T\XK8E0Z'XYJ">?2[5G!Z$XYCL4(;'78AS@XQD<?
MS+\S->:9LQE]V%PW(IIH.MGQ-$A'*B'MCDNGA,I3;:;""L\#!*4#'NDT@\F
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M">A78?G01EIU1<5'BXD#6(])3O%G3ZRCQ(B,DLS=';Y]31)'WB**<X%_Y.?
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M17Y7758H#HVRMY9 >1@ #7P#7 @!/!0Q]4V,%1=N,[D[QSLT::YG*1N8:UN
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M+?11+ZAH.)S\)15MX;2]J*+5KDN\=<9/[:?C%YMODM6KM(]?_!]02P,$%
M  @ I3RD5,7YC'6K!@  X#   !4   !N8FEX+3(P,C(P-3 T7W!R92YX;6S5
MFEM/XU@2Q]_Y%-G,ZQYR[A?4,&*9[A5:9AIU,^K1OD3G4B=8[=C(,0U\^RT;
MF.'2S%HX$NZ77)QC5]6_?JG4*>?=S]?K<O8-FDU15_MSMDOG,ZABG8IJM3__
M_>P#L?.?#W9VWOV#D#_^]>ED]DL=+]=0M;.C!GP+:795M.>S+PDV7V>YJ=>S
M+W7SM?CF"3GH3SJJ+VZ:8G7>SCCE_.FGS1Y5-F6O.)'*"R*MYR0X\$0HRH/Q
ME#-K_KG:$SKRG(PD5CE-)'- 7.*<&&N33TDPZF\O6A;5U[WN(?@-S#"X:M._
MW9^?M^W%WF)Q=76U>QV:<K=N5@M.J5C<KY[?+;]^MOY*]*N9<V[1?_KGTDWQ
MO85X6;;XX]>3S_$<UIX4U:;U5>P,;(J]37_PI(Z^[37_OW[-7ES1O2/WRTAW
MB#!.!-N]WJ3YP<YL=BM'4Y?P"?*L>_[]T_$CDQ5<-G5LB@IV8[U>=$L61S4"
M@<[V)[<W%[ _WQ3KBQ+NCYTWD/?G52BN29=5JJCL3/YT>^+B+\L7#6P0EC[2
M$SQP=WYGY35>P'4+58+;V.YME'5\M*CLE*W_/+/T <K^Z#)!L>RO>A@V;>-C
MN[0Y"!=D)"KG0&2(CC@A#4IHJ6,@!##V..C.Z0UZW2=B W%W57];X(4Q(9QU
M+SI%^@3\],S<K3*O\_O^>W>&:Y<J,B-CR,0"CT1Z"\0S<"0F1KG7/-'L1KG]
MT-ICKQ]F]+")L[I)T&#AN#?GF_@LNX^AO5NQN/ -7HC$\Z),]V=W%60;N6KK
M+2AWFQ9T=S[#J#,T#:23VZR\&%P?68OE%/J5V\CX*31%G=Y7Z1>LMTM%69"2
M)A(DS42*R(D'@_%HR,+S%'7V6TG]([.#&.#39^#U6KXQ#.^KMFAO/L&JZ)2H
MVM_\&I8AJ)# :V(I$BTQ&F*-LETD468&V5 8Q<+WK Y"04P7A=%*3H*$8^S1
MFHNZZ87_C/K#47U9M<W-49U@Z9E)E!I'DK<8CH^*>"4HR330Z$,&$_46P/A;
M)P9Q(J?.R?9TG@0V'XH2?KM<!VB643*!338*X3T0B9BC+@Y#,5(RX$P**[?
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M+Z&ZZFFK%"PY]LUC_1@-#"*[J'E1.;T=@<O.!<)W76G$-VHDP!J1(@"[(,7
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MOYR_11)F'&-Q_T.!>1GH@VO=D&J E/<KHT$,C/R)MG&0*9+H'RSHH$6NHMO
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M3C658OG_CS^2J[#\2<^9]755R94O(CQJT&_P6*+(0^J;3*;2Y%UW0C)./D;
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M5]@M^-SW=VWA#^"?;MP+?OX_4$L! A0#%     @ I3RD5-UL\:EV%   MGT
M !$              ( !     &YB:7@M,C R,C U,#0N:'1M4$L! A0#%
M  @ I3RD5(Q@TBEL @  = <  !$              ( !I10  &YB:7@M,C R
M,C U,#0N>'-D4$L! A0#%     @ I3RD5%AL^:,^1@  TD<  !0
M     ( !0!<  &YB:7@M,C R,C U,#1?9S$N:G!G4$L! A0#%     @ I3RD
M5"R68V%3"@  &%T  !4              ( !L%T  &YB:7@M,C R,C U,#1?
M;&%B+GAM;%!+ 0(4 Q0    ( *4\I%3%^8QUJP8  . P   5
M  "  39H  !N8FEX+3(P,C(P-3 T7W!R92YX;6Q02P$"% ,4    " "E/*14
M,Q"4H3@M  !/8 ( &@              @ $4;P  ;F)I>"TR,#(R,S,Q97AH
A:6)I=#DY,2YH=&U02P4&      8 !@". 0  A)P

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
